id string | name string | acronym string | kind string | status string | setting string | intervention string | intervention_class string | comparator string | dose_regimen string | duration string | population dict | primary_outcome string | result string | lead_organization string | sponsor_or_funder string | registration list | start_year int64 | end_year int64 | sources list | summary string | notes string | parent_id string | tags list | extracted_by string |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
l-deprenyl-beagle-survival-1997 | L-deprenyl 1 mg/kg daily versus placebo survival study in 82 paired beagles | null | controlled_trial | completed | null | L-deprenyl | drug | placebo | 1 mg/kg L-deprenyl orally once daily | 2 years and 10 weeks | {
"n": 82,
"n_note": "82 beagles allotted to 41 pairs; elderly subset aged 10-15 years at start and treated for at least 6 months: 15 L-deprenyl and 18 placebo dogs",
"breed": "beagle",
"age": "2.8 to 16.4 years",
"other": "Weight 6.3 to 15.8 kg"
} | Survivorship (survival to the conclusion of the study) | When survivorship for all dogs in the study was analyzed there was no significant difference between the L-deprenyl and placebo treated groups. In the subset of elderly dogs, dogs in the L-deprenyl group survived longer (p < 0.05) than dogs in the placebo group: twelve of 15 (80%) L-deprenyl dogs survived to the conclu... | null | null | [] | null | null | [
{
"type": "pmid",
"pmid": "9307048",
"slug": null,
"doi": "10.1016/s0024-3205(97)00611-5",
"title": "Treatment with L-deprenyl prolongs life in elderly dogs.",
"year": 1997,
"role": "results",
"quotes": [
"Eighty two beagle dogs ranging in age from 2.8 to 16.4 years and in weig... | Eighty-two beagles aged 2.8 to 16.4 years were allotted to 41 pairs and given placebo or 1 mg/kg L-deprenyl orally once daily for 2 years and 10 weeks. Across all dogs there was no significant difference in survivorship between the groups. In a subset of elderly dogs aged 10 to 15 years at the start who received tablet... | The abstract describes pair allotment and a placebo comparator but does not state randomization, blinding, the housing setting or the funder. The survival benefit is reported in an elderly subset analysed within the same study. | null | [
"l-deprenyl",
"lifespan",
"beagle",
"drug",
"placebo-controlled"
] | claude-subagent-batch-A |
selegiline-cds-open-label-2001 | Selegiline hydrochloride (Anipryl) in dogs with cognitive dysfunction syndrome: noncomparative open-label study | null | single_arm_trial | completed | null | Selegiline hydrochloride (Anipryl), oral | drug | None (noncomparative open-label study) | 0.5 to 1.0 mg/kg orally once daily | 60 days | {
"n": 641,
"n_note": "641 dogs treated",
"breed": null,
"age": null,
"other": "Clinical signs consistent with canine cognitive dysfunction syndrome (CDS)"
} | Overall improvement and response by clinical sign on days 30 and 60; adverse events | Response to selegiline treatment on days 30 and 60 were similar. On day 60, 77.2% of dogs showed an overall improvement; response to treatment by clinical sign ranged from 67.8% (activity or sleep/wake cycle) to 77.8% (disorientation and interaction with family members). Diarrhea (4.2%), anorexia (3.6%), and vomiting/s... | null | null | [] | null | null | [
{
"type": "pmid",
"pmid": "19753696",
"slug": null,
"doi": null,
"title": "A noncomparative open-label study evaluating the effect of selegiline hydrochloride in a clinical setting.",
"year": 2001,
"role": "results",
"quotes": [
"Six hundred forty-one dogs with clinical signs c... | In a single-arm open-label study, 641 dogs with clinical signs of canine cognitive dysfunction syndrome received oral selegiline hydrochloride at 0.5 to 1.0 mg/kg once daily for 60 days. Responses at days 30 and 60 were similar; on day 60, 77.2% of dogs showed overall improvement, with sign-specific response rates from... | Kind follows the title wording (noncomparative open-label study). The title places the study in a clinical setting, but the abstract does not state whether dogs were client-owned; sponsor not stated. | null | [
"cognition",
"drug",
"selegiline",
"cognitive-dysfunction",
"open-label"
] | claude-subagent-batch-B |
n6-n3-fatty-acids-vitamin-e-immune-geriatric-beagles-2003 | Dietary n-6:n-3 fatty acid ratio and vitamin E on immune response and T cell subpopulations of healthy geriatric Beagles | null | controlled_trial | completed | null | Foods with low (1.4:1) or high (40:1) n-6 to n-3 fatty acid ratios in combination with three concentrations of all rac-alpha-tocopheryl acetate | diet_or_supplement | Factorial comparison across the diet groups (no separate untreated control stated) | n-6 to n-3 fatty acid ratio 1.4:1 or 40:1; all rac-alpha-tocopheryl acetate low 17 mg/kg of food, medium 101 mg/kg, high 447 mg/kg; keyhole limpet hemocyanin inoculation at 13 and 15 weeks | 17 weeks | {
"n": 32,
"n_note": null,
"breed": "Beagle",
"age": "7- to 10-year old",
"other": "healthy female"
} | Immune functions and T cell subpopulations (percentages of CD8+ T cells, CD4+ to CD8+ ratio) and delayed-type hypersensitivity (DTH) skin test response | After 12 weeks, dogs consuming low concentrations of alpha-tocopheryl acetate had lower percentages of CD8+ T cells and higher CD4+ to CD8+ ratios than dogs on medium or high concentrations; dogs consuming low n-3 fatty acids with medium alpha-tocopheryl acetate had the largest DTH response. The authors conclude that a... | null | null | [] | null | null | [
{
"type": "pmid",
"pmid": "12828263",
"slug": null,
"doi": "10.2460/ajvr.2003.64.762",
"title": "Effects of dietary n-6 and n-3 fatty acids and vitamin E on the immune response of healthy geriatric dogs.",
"year": 2003,
"role": "results",
"quotes": [
"To determine the effect of... | Thirty-two healthy female Beagles aged 7 to 10 years were fed for 17 weeks foods combining a low (1.4:1) or high (40:1) n-6 to n-3 fatty acid ratio with low, medium or high alpha-tocopheryl acetate, and were inoculated with keyhole limpet hemocyanin at weeks 13 and 15, to determine effects on immune function and T cell... | Borderline inclusion: the abstract objective names immune function in healthy dogs rather than aging, but the title and the 7- to 10-year-old geriatric population place it in the immunosenescence context. The abstract does not describe randomization; the PubMed publication type lists Randomized Controlled Trial. No ful... | null | [
"diet",
"vitamin-e",
"omega-3",
"immunosenescence",
"t-cells",
"beagle"
] | claude-subagent-batch-C |
beagle-antioxidant-cofactor-landmark-discrimination-2004 | Prior experience, antioxidants and mitochondrial cofactors in aged beagles (landmark discrimination) | null | randomized_controlled_trial | completed | null | Food providing higher levels of vitamin E (antioxidants and mitochondrial cofactors) | diet_or_supplement | null | null | null | {
"n": null,
"n_note": null,
"breed": null,
"age": "aged dogs",
"other": null
} | Performance on landmark-discrimination tasks; serum vitamin E concentrations | providing higher levels of vitamin E in food resulted in higher serum vitamin E concentrations and improved performance on landmark-discrimination tasks in aged dogs. Factors other than vitamin E also contributed to the response but remain undefined. | null | null | [] | null | null | [
{
"type": "pmid",
"pmid": "15150725",
"slug": null,
"doi": null,
"title": "Prior experience, antioxidants, and mitochondrial cofactors improve cognitive function in aged beagles.",
"year": 2004,
"role": "results",
"quotes": [
"Results of this study support the free-radical theo... | This study fed aged dogs food providing higher levels of vitamin E and tested them on landmark-discrimination tasks. Higher dietary vitamin E produced higher serum vitamin E concentrations and improved landmark-discrimination performance, although factors other than vitamin E also contributed to the response. The publi... | The abstract is a two-sentence summary. Kind is recorded as randomized_controlled_trial from the PubMed publication type (Randomized Controlled Trial; Clinical Trial); the title names prior experience, antioxidants and mitochondrial cofactors in aged beagles, so breed is Beagle by title only. Judged separate from the l... | null | [
"cognition",
"antioxidant-diet",
"vitamin-e",
"beagle"
] | claude-subagent-batch-B |
ginseng-brewers-yeast-gerivet-geriatric-dogs-2007 | Panax Ginseng with brewers' yeast (Gerivet) as a stimulant for geriatric dogs | null | randomized_controlled_trial | completed | client_owned | Ginseng (Panax Ginseng) together with brewers' yeast (Saccharomyces cerevisae) | diet_or_supplement | Brewers' yeast only (control group, but not a true placebo); an external group was also used for comparison | null | 8 weeks of treatment, with follow-up at 12 and 16 weeks | {
"n": 80,
"n_note": "Ginseng plus yeast n = 41; yeast-only control n = 39",
"breed": null,
"age": null,
"other": null
} | Owner questionnaire and three visual analogue scales: seven primary (mental) outcome measures and secondary (physical) outcome measures, as change from baseline | Panax Ginseng plus yeast significantly improved all evaluated variables within the group. Four of the seven primary (mentally) outcome measures were significant when comparing the changes in the Ginseng group with the control group, and six of the seven were significant when compared to an external group. As the second... | null | null | [] | null | null | [
{
"type": "pmid",
"pmid": "17610402",
"slug": null,
"doi": "10.1111/j.1365-2885.2007.00876.x",
"title": "Panax Ginseng in combination with brewers' yeast (Gerivet) as a stimulant for geriatric dogs: a controlled-randomized blinded study.",
"year": 2007,
"role": "results",
"quotes": [... | Eighty dogs were given either Panax Ginseng with brewers' yeast (n = 41) or brewers' yeast alone as a non-placebo control (n = 39) for 8 weeks, with blinded owners scoring a questionnaire and three visual analogue scales weekly and at 12 and 16 weeks of follow-up. Ginseng plus yeast improved all variables within its gr... | Kind is recorded as randomized_controlled_trial from the title (controlled-randomized blinded study) and PubMed publication type; the abstract describes blinded owners and a control group that was not a true placebo. The title describes the dogs as geriatric and names the product Gerivet; the abstract gives no ages or ... | null | [
"cognition",
"nutraceutical",
"ginseng",
"geriatric",
"client-owned"
] | claude-subagent-batch-B |
beagle-phosphatidylserine-ginkgo-nutraceutical-crossover-2008 | Nutraceutical supplement (phosphatidylserine, Ginkgo biloba, vitamin E, pyridoxine) for short-term memory in aged beagles | null | crossover_trial | completed | null | Commercially available nutraceutical supplement containing phosphatidylserine, Ginkgo biloba, vitamin E, and pyridoxine | diet_or_supplement | Control substance | null | null | {
"n": 9,
"n_note": "9 aged beagles tested; split into two groups for the crossover phases",
"breed": "Beagle",
"age": "aged",
"other": null
} | Performance accuracy on a delayed-non-matching-to-position task (short-term visuospatial memory) | Performance accuracy was significantly improved in supplemented dogs compared with control dogs and the effect was long lasting. | null | null | [] | null | null | [
{
"type": "pmid",
"pmid": "18481547",
"slug": null,
"doi": null,
"title": "Improvement of short-term memory performance in aged beagles by a nutraceutical supplement containing phosphatidylserine, Ginkgo biloba, vitamin E, and pyridoxine.",
"year": 2008,
"role": "results",
"quotes": ... | Nine aged beagles were tested on a delayed-non-matching-to-position task of short-term visuospatial memory, then given a commercial nutraceutical containing phosphatidylserine, Ginkgo biloba, vitamin E and pyridoxine or a control substance in a two-phase crossover design. Performance accuracy was significantly improved... | Dose, phase duration, setting and funding are not stated in the abstract. | null | [
"cognition",
"nutraceutical",
"beagle",
"memory",
"crossover"
] | claude-subagent-batch-B |
same-cognitive-decline-rct-2008 | S-adenosylmethionine (Novifit) for age-related mental decline in dogs: double-blinded placebo-controlled trial | null | randomized_controlled_trial | completed | null | Oral S-adenosylmethionine (SAMe) tosylate tablets (Novifit tablets, Virbac) | diet_or_supplement | Identical placebo tablets | 18 mg/kg SAMe tosylate, oral tablets, for 2 months | 2 months | {
"n": 36,
"n_note": "36 dogs: SAMe n=17, placebo n=19",
"breed": null,
"age": "older than 8 years",
"other": "Signs of cognitive dysfunction for at least 1 month; concurrent behavioral treatment forbidden"
} | 14-item standardized questionnaire evaluating behavior and locomotion difficulties (activity, awareness, aggregate mental impairment score) | Compared with the placebo group, SAMe-treated dogs showed greater improvement in activity (41.7% versus 2.6% after 4 weeks, P<.0003; 57.1% versus 9.0% after 8 weeks, P<.003) and awareness (33.3% versus 17.9% after 4 weeks, P<.05; 59.5% versus 21.4% after 8 weeks, P<.01). The aggregate mental impairment score was reduce... | null | null | [] | null | null | [
{
"type": "pmid",
"pmid": "18597245",
"slug": null,
"doi": null,
"title": "Effect of S-adenosylmethionine tablets on the reduction of age-related mental decline in dogs: a double-blinded, placebo-controlled trial.",
"year": 2008,
"role": "results",
"quotes": [
"Oral S-adenosylm... | Thirty-six dogs older than 8 years with at least one month of cognitive dysfunction signs received 18 mg/kg oral SAMe tosylate (n=17) or identical placebo tablets (n=19) for 2 months, with behavior and locomotion scored on a 14-item questionnaire. SAMe-treated dogs improved more than placebo in activity and awareness a... | Kind is recorded as randomized_controlled_trial from the title (double-blinded, placebo-controlled trial) and the PubMed publication type; the abstract does not describe the randomization procedure. The product was supplied as Novifit tablets (Virbac); sponsor and setting are not stated. | null | [
"cognition",
"nutraceutical",
"same",
"cognitive-dysfunction",
"placebo-controlled"
] | claude-subagent-batch-B |
beagle-antioxidant-diet-behavioral-enrichment | Antioxidant-fortified diet and behavioral enrichment in aged beagles (longitudinal study) | null | controlled_trial | completed | null | Antioxidant-fortified food (a broad spectrum of antioxidants and mitochondrial enzymatic cofactors) and a program of behavioral enrichment (increased exercise, environmental enrichment, and a series of learning tasks), alone and combined in a 2 x 2 factorial design | combination | Control food and control (normal level) environment | null | 2-year longitudinal study; cognitive testing after 6 months, 1 year and 2 years of treatment | {
"n": 48,
"n_note": "48 aged dogs assigned to four groups of 12 (CC, CE, AC, AE); two additional groups of young behaviorally enriched dogs (control or fortified food); the immune sub-analysis reports n=21 geriatric dogs",
"breed": "Beagle",
"age": "9-12 years (aged groups)",
"other": "Aged groups were forme... | Discrimination and reversal learning (oddity discrimination after 6 months; size discrimination and reversal after 1 year; black/white discrimination after 2 years); neutrophil phagocytosis and lymphocyte proliferation in an immune sub-analysis | At one and two years, the aged combined treatment group showed more accurate learning than the other aged groups. Discrimination learning was significantly improved by behavioral enrichment. Reversal learning was improved by both behavioral enrichment and dietary fortification. By contrast, the fortified food had no ef... | null | null | [] | null | null | [
{
"type": "pmid",
"pmid": "12392778",
"slug": null,
"doi": "10.1016/s0197-4580(02)00020-9",
"title": "Dietary enrichment counteracts age-associated cognitive dysfunction in canines.",
"year": 2002,
"role": "results",
"quotes": [
"we studied the effects of dietary antioxidants a... | A longitudinal controlled study in beagles tested an antioxidant-fortified food and a program of behavioral enrichment, alone and combined, against control food and a control environment in a 2 x 2 factorial design. Forty-eight aged dogs (9-12 years) were assigned from baseline cognitive scores into four cognitively eq... | Grouped as one study: the 2004 and 2005 papers report the 1-year and 2-year cognitive results of the same longitudinal investigation, the 2006 paper reports an immune sub-analysis of its 2-year cohort (n=21), and the 2007 and 2009 reviews summarise the same intervention study. The 2002 paper reports the 6-month oddity-... | null | [
"cognition",
"antioxidant-diet",
"enrichment",
"beagle",
"immunosenescence",
"longitudinal"
] | claude-subagent-batch-B |
purina-lifetime-diet-restriction | Lifetime 25% diet restriction paired-feeding study in 48 Labrador Retrievers | null | randomized_controlled_trial | completed | null | 25% diet restriction (each restricted dog fed 75% of the food consumed by its control-fed pair mate; same diet, only the quantity differed) | diet_restriction | Control-fed (CF) pair mate | 25% less food than the pair-mate (75% of the total food consumed by the control-fed pair mate); feeding began at age 8 weeks | From 8 weeks of age until death (lifetime); body composition measured annually until 12 years of age; immune parameters monitored from 4 to 13 years | {
"n": 48,
"n_note": "48 dogs from seven litters, paired at 6 weeks by sex and weight and allotted to 2 groups of 24 (diet-restricted and control-fed)",
"breed": "Labrador Retriever",
"age": "Paired at age 6 weeks; feeding protocol from 8 weeks of age until death",
"other": "Puppies from 7 litters; weight- an... | Life span (median: age when 50% of dogs deceased; maximum: age when 90% deceased), age at onset of chronic disease, and markers of aging (serum biochemistry, body condition, body composition) | Median life span was significantly longer for dogs in which food was restricted (1.8 years longer median lifespan among diet-restricted dogs), and the onset of clinical signs of chronic disease generally was delayed, especially osteoarthritis. CR retarded age-related declines in lymphoproliferative responses and lympho... | null | null | [] | null | null | [
{
"type": "pmid",
"pmid": "11991408",
"slug": null,
"doi": "10.2460/javma.2002.220.1315",
"title": "Effects of diet restriction on life span and age-related changes in dogs.",
"year": 2002,
"role": "results",
"quotes": [
"To evaluate the effects of 25% diet restriction on life ... | Forty-eight Labrador Retrievers from seven litters were paired by sex and weight, and one dog in each pair was randomly assigned to receive 25% less food than its control-fed pair mate from 8 weeks of age until death. Median life span was significantly longer in the diet-restricted dogs (1.8 years longer), and the onse... | Four papers report one lifetime study: the 2002 JAVMA results paper, the 2006 immunosenescence sub-analysis, the 2008 two-decade review and the 2009 elbow osteoarthritis sub-analysis. The abstracts do not name the sponsoring organization, the housing setting or the calendar years; the slug follows the registry's workin... | null | [
"diet-restriction",
"lifespan",
"labrador-retriever",
"immunosenescence",
"osteoarthritis",
"body-composition"
] | claude-subagent-batch-A |
skn-cell-therapy-canine-cognitive-dysfunction-sydney-2022 | Autologous skin-derived neural precursor (SKN) cell therapy for canine cognitive dysfunction in older companion dogs (DOGS + CELLS trial) | DOGS + CELLS | single_arm_trial | completed | client_owned | Direct microinjection of autologous skin-derived neuroprecursors (SKNs) into the bilateral hippocampus using MRI-guided stereotaxis | cell_or_gene_therapy | None (open-label, no control arm); post-mortem histology compared with a brain bank (N = 12) of untreated aged dogs | 250,000 autologous SKNs microinjected into the bilateral hippocampus | 3-month primary endpoint; clinical follow-up up to 2 years | {
"n": 6,
"n_note": "N = 8 recruited and N = 6 treated over 8 years; modified intention-to-treat analysis N = 5",
"breed": null,
"age": "aged 10-16 years",
"other": "older companion (community-dwelling) dogs with definitive diagnosis of Canine Cognitive Dysfunction (CCD); 2 female, 4 male"
} | Change in the Canine Cognitive Dysfunction Rating Scale (CCDR) from baseline to 3 months post treatment; safety assessed clinically | Four out-of-five dogs improved on the primary clinical CCDR endpoint, three fell below diagnostic threshold, and two underwent full syndromal reversal lasting up to 2 years (modified ITT paired T test = 3.06, df = 4, p = 0.038). At post mortem, hippocampal synaptic density was nine standard deviations above non-treated... | University of Sydney | null | [
{
"registry": "preclinicaltrials.eu",
"id": "PCTE0000169",
"url": null
}
] | 2,012 | 2,020 | [
{
"type": "pmid",
"pmid": "35715872",
"slug": null,
"doi": "10.1186/s13287-022-02933-w",
"title": "Autologous skin-derived neural precursor cell therapy reverses canine Alzheimer dementia-like syndrome in a proof of concept veterinary trial.",
"year": 2022,
"role": "results",
"quotes... | An open-label Phase 1/2A veterinary trial at the University of Sydney, run over 2012-2020, treated six older companion dogs (aged 10-16 years) with a definitive diagnosis of canine cognitive dysfunction by MRI-guided microinjection of 250,000 autologous skin-derived neural precursor cells into both hippocampi. The prim... | Borderline on framing: the authors present this as treatment of a canine Alzheimer dementia-like syndrome (CCD) in older dogs; included because CCD is the age-related cognitive decline of dogs. Single-arm, open-label, with no control arm; a companion aged-rat study is reported in the same paper. No funding statement lo... | null | [
"stem-cells",
"cell-therapy",
"cognition",
"ccd",
"hippocampus",
"surgery"
] | claude-subagent-batch-C |
golden-retriever-lifetime-study | Golden Retriever Lifetime Study (Morris Animal Foundation) | GRLS | longitudinal_cohort | ongoing | client_owned | null | none | null | null | lifetime follow-up; baseline enrolment June 2012 to April 2015 | {
"n": 3044,
"n_note": "completed baseline enrolment; as of 31 May 2021, 2,251 engaged, 352 died, 441 lost to follow-up",
"breed": "Golden Retriever",
"age": "6 months to 2 years at enrolment",
"other": "United States"
} | incidence of hemangiosarcoma, lymphoma, osteosarcoma and high-grade mast cell tumors; secondary outcomes include other cancers, hypothyroidism, epilepsy, atopy, otitis externa, hip dysplasia, heart failure and renal failure | null | Morris Animal Foundation | Morris Animal Foundation | [] | 2,012 | null | [
{
"type": "europepmc",
"pmid": "35679242",
"slug": null,
"doi": "10.1371/journal.pone.0269425",
"title": "Cohort profile: The Golden Retriever Lifetime Study (GRLS).",
"year": 2022,
"role": "design",
"quotes": [
"a prospective cohort study investigating nutritional, environment... | The Golden Retriever Lifetime Study is a prospective cohort of 3,044 US Golden Retrievers enrolled between 2012 and 2015 at 6 months to 2 years of age, followed for life with annual owner and veterinarian questionnaires, examinations and biobanked samples. Its primary outcomes are four cancers; secondary outcomes inclu... | A cancer-focused lifetime cohort rather than an aging study by design, but the only breed-wide lifetime cohort with biobanking in dogs; included as an aging cohort resource. | null | [
"cohort",
"golden-retriever",
"cancer",
"biobank",
"lifetime"
] | claude-hand-curated |
mct-fish-oil-carnitine-beagles-serum-aging-2012 | Medium-chain triglyceride, fish oil and L-carnitine enriched foods against age-associated serum fatty acid and carnitine changes in healthy Beagles | null | randomized_controlled_trial | completed | laboratory_colony | Foods enriched with medium-chain triglycerides (MCT), fish oil and L-carnitine (two treatment foods) | diet_or_supplement | Control food | Treatment diets contained added L-carnitine (300 mg/kg) and 0.6% (treatment food 1) or 1.5% (treatment food 2) added fish oil; treatment food 2 also had increased MCT from coconut oil, added corn oil and reduced animal fat | 6 months | {
"n": 41,
"n_note": "41 dogs randomized to 3 study groups; 3 removed during the study for unrelated reasons; age categories: mature adults (7 years and under) and geriatric adults (older than 7 years)",
"breed": "Beagle",
"age": "mean age 9.9 years (range 3.1 to 14.8)",
"other": "healthy; equal numbers of fe... | Serum fatty acid composition (gas chromatography) and serum carnitine metabolites (metabolomic profiling); body composition by dual energy x-ray absorptiometry | Serum concentrations of carnitine metabolites were decreased in geriatric (>7 years) vs. mature adult (<= 7 years) dogs, and supplementation with L-carnitine attenuated the effects of aging; serum eicosapentaenoic and docosahexaenoic FA increased in a dose-dependent manner; no change in total-lean-body weight, serum to... | Hill's Pet Nutrition, Inc., Topeka, KS, USA | null | [] | null | null | [
{
"type": "pmid",
"pmid": "23145181",
"slug": null,
"doi": "10.1371/journal.pone.0049510",
"title": "Feeding healthy beagles medium-chain triglycerides, fish oil, and carnitine offsets age-related changes in serum fatty acids and carnitine metabolites.",
"year": 2012,
"role": "results",
... | Forty-one healthy Beagles (mean age 9.9 years, range 3.1 to 14.8) housed at a Hill's colony were randomized to a control food or one of two foods enriched with L-carnitine and fish oil, the second also containing medium-chain triglycerides, for 6 months. The stated purpose was to test whether these foods offset age-ass... | No funding statement appears in the full text; the protocol was approved by Hill's IACUC and the foods were prepared by Hill's Pet Nutrition. | null | [
"supplement",
"diet",
"fish-oil",
"carnitine",
"mct",
"metabolomics",
"colony"
] | claude-subagent-batch-C |
astaxanthin-mitochondrial-function-beagles-2013 | Dietary astaxanthin and age-associated mitochondrial dysfunction in young and geriatric Beagles | null | controlled_trial | completed | null | Astaxanthin fed daily | diet_or_supplement | 0 mg astaxanthin | 0 or 20 mg astaxanthin daily for 16 wk | 16 wk (blood sampled wk 0, 8 and 16) | {
"n": 28,
"n_note": "n=14 per age group (young and geriatric), fed 0 or 20 mg astaxanthin; group sizes per treatment within age group not stated",
"breed": "Beagle",
"age": "young (2.97±0.01 yr) and geriatric (10.71±0.01 yr)",
"other": "healthy female"
} | Leukocyte mitochondrial function (membrane permeability, ATP production, cytochrome c oxidase/reductase, mitochondrial number) and plasma oxidative stress markers | Mitochondrial function improved in both young and geriatric dogs by increasing (P<0.05) ATP production, mitochondria mass, and cytochrome c oxidoreductase activity, especially in geriatric dogs compared with young dogs; astaxanthin also increased the reduced to oxidized glutathione ratio in young dogs and decreased nit... | null | null | [] | null | null | [
{
"type": "pmid",
"pmid": "23100599",
"slug": null,
"doi": "10.2527/jas.2012-5341",
"title": "Astaxanthin modulates age-associated mitochondrial dysfunction in healthy dogs.",
"year": 2013,
"role": "results",
"quotes": [
"Young (2.97±0.01 yr; 8.16±0.15 kg BW) and geriatric (10.... | Healthy female Beagles in a young (about 3 years) and a geriatric (about 10.7 years) group, 14 per age group, were fed 0 or 20 mg astaxanthin daily for 16 weeks to examine modulation of age-associated mitochondrial dysfunction. Leukocyte mitochondrial function and plasma oxidative markers were measured at weeks 0, 8 an... | The abstract does not describe randomization or blinding; the PubMed publication type for this record lists Randomized Controlled Trial. No full text available in the corpus; the total n of 28 is 14 per age group across two age groups. | null | [
"supplement",
"astaxanthin",
"mitochondria",
"oxidative-stress",
"beagle"
] | claude-subagent-batch-C |
mannac-place-learning-crossover-2014 | N-acetyl-D-mannosamine (ManNAc) for age-related decline in place learning in dogs | null | crossover_trial | completed | null | N-acetyl-D-mannosamine (ManNAc), oral capsule | drug | Glucose capsule (control, equivalent calorie value) | One capsule containing 250 mg ManNAc or glucose orally once a day for 2 months | 2-month courses of each treatment in a crossover design with a 1-month washout period | {
"n": 5,
"n_note": "5 dogs with low cognitive levels (1 male, 4 females); statistical analyses on n=4 or 5",
"breed": "Labrador Retriever",
"age": "93.60 ± 11.98 months",
"other": "Retired or demonstration dogs living at the Japan Guide Dog Association facility, in good health on medical examination"
} | Number of error trials in a place-learning test; active-resting cycle (daytime/nighttime motor activity ratio) | ManNAc treatment significantly reduced the number of error trials in the place-learning test, especially in the first month of administration. Three ManNAc-treated dogs also showed improvement in the active-resting cycle. In conclusion, ManNAc treatment appears to alleviate age-related cognitive dysfunction. | null | null | [] | null | null | [
{
"type": "pmid",
"pmid": "24430654",
"slug": null,
"doi": "10.1292/jvms.13-0351",
"title": "N-acetyl-D-mannosamine treatment alleviates age-related decline in place-learning ability in dogs.",
"year": 2014,
"role": "results",
"quotes": [
"This study aimed to investigate the th... | Five older Labrador Retrievers (93.60 ± 11.98 months) with low cognitive levels, living at a guide dog facility, received 2-month courses of 250 mg oral ManNAc and of glucose control in a crossover design with a 1-month washout. ManNAc significantly reduced place-learning error trials, especially in the first month, an... | Dogs were retired or demonstration dogs at the Japan Guide Dog Association facility, so setting is neither a laboratory colony nor client-owned and is left null. ManNAc is described by the authors as a therapeutic agent, so intervention_class is recorded as drug. Full-text quotes include the Markdown line breaks of the... | null | [
"cognition",
"mannac",
"place-learning",
"crossover",
"labrador-retriever"
] | claude-subagent-batch-B |
hills-functional-foods-renal-function-geriatric-colony-2016 | Renal protective foods with functional food bioactives against age-associated decline in renal function (Hill's geriatric Beagle colony) | null | randomized_controlled_trial | completed | laboratory_colony | Control renal protective food supplemented with increasing amounts of functional food bioactives (fish oil, lipoic acid, fruits and vegetables, higher quality protein sources): functional foods FF1 and FF2 | diet_or_supplement | Traditional renal protective food (control; energy dense and mildly protein-restricted; Hill's Science Diet Mature Adult) | Both functional foods contained 0.5% fish oil and 100 mg/kg lipoic acid; FF1 contained 2.75% fruits and vegetables, 7% egg protein and 7.5% wet meat chicken; FF2 contained 7.5% fruits and vegetables, 14% egg protein, 10% wet meat chicken and 955 IU/kg a-tocopherol acetate | 6 months | {
"n": 111,
"n_note": "81 geriatric dogs randomly assigned to three foods (n = 27 per group) after blocking for sex, plus 30 mature-adult dogs as a cross-sectional comparison group",
"breed": "Beagle",
"age": "geriatric: mean age 10.4, range 7.9-14.2 years; mature adult: mean age 5.0, range 3.3-6.9 years",
"o... | Glomerular filtration rate (GFR), lean body percent (LB%) by dual energy x-ray absorptiometry, and circulating biomarkers and metabolites including symmetric dimethylarginine (SDMA) | Geriatric dogs consuming all three foods increased (P<0.001) GFR over time; group averages ranged from 13.0-16.9%. Dogs fed the highest supplemented level of bioactives (FF2) had lower (P<0.001) SDMA concentrations (-14.3%). Feeding functional foods did not alter body weight, but increased (P<0.001) serum protein conce... | Pet Nutrition Center, Hill's Pet Nutrition, Inc., Topeka, KS | Hill's Pet Nutrition, Inc. | [] | null | null | [
{
"type": "pmid",
"pmid": "27925141",
"slug": null,
"doi": "10.1007/s12603-015-0636-3",
"title": "Nutritional Interventions that Slow the Age-Associated Decline in Renal Function in a Canine Geriatric Model for Elderly Humans.",
"year": 2016,
"role": "results",
"quotes": [
"To ... | Eighty-one healthy geriatric Beagles (mean 10.4 years) at the Hill's Pet Nutrition colony were randomly assigned, after blocking for sex, to a control renal protective food or to one of two functional foods (FF1, FF2) with increasing amounts of fish oil, lipoic acid, fruits and vegetables and higher quality protein, fo... | Separate from the client-owned test-food study (PMID 27088214), which used different dogs, setting and comparator. | null | [
"diet",
"supplement",
"renal",
"sdma",
"gfr",
"fish-oil",
"lipoic-acid",
"colony"
] | claude-subagent-batch-C |
hills-test-food-sdma-client-owned-geriatric-dogs-2016 | Test food designed to promote healthy aging vs owner's-choice foods on serum SDMA and creatinine in client-owned geriatric dogs | null | randomized_controlled_trial | completed | client_owned | Test food (renal protective food) containing functional lipids (fish oil), antioxidants (lipoic acid, vitamins C and E), L-carnitine, botanicals (fruits and vegetables), controlled sodium concentration and high quality protein sources | diet_or_supplement | Owner's-choice foods (non-nutritionally controlled cohort) | null | 6 months (biomarkers evaluated at baseline, 3 and 6 months) | {
"n": 210,
"n_note": "210 dogs reported in the abstract; 255 dogs enrolled per the full text (small: 26 test food / 25 owner's-choice; medium: 25 / 24; large: 78 / 77)",
"breed": null,
"age": "small (6.8 to 11.4 kg) and medium dogs (11.5 to 22.7 kg) were >= 9 years, dogs >22.7 kg were >= 7 years at baseline; e... | Serum symmetric dimethylarginine (SDMA) and creatinine (Cr) concentrations, plus urinalysis, at baseline, 3 and 6 months | Only dogs consuming test food showed significant decreases in serum SDMA and Cr concentrations (both P <= 0.05) across time. Among 18 dogs with increased SDMA but normal Cr (consistent with IRIS Stage 1 CKD), the decreases in serum SDMA and Cr were significant (both P = 0.03) only for dogs fed test food. | Hill's Pet Nutrition, Inc., Topeka, KS (protocol approval and test food); contract research organization with seventeen US veterinary clinics | null | [] | null | null | [
{
"type": "pmid",
"pmid": "27088214",
"slug": null,
"doi": "10.1371/journal.pone.0153653",
"title": "Positive Impact of Nutritional Interventions on Serum Symmetric Dimethylarginine and Creatinine Concentrations in Client-Owned Geriatric Dogs.",
"year": 2016,
"role": "results",
"quot... | A prospective 6-month feeding study in client-owned geriatric dogs recruited through seventeen US veterinary clinics randomized dogs to a Hill's test food designed to promote healthy aging (fish oil, lipoic acid, vitamins C and E, L-carnitine, fruits and vegetables, controlled sodium, high quality protein) or to owner'... | The sponsor is not named in the text (veterinarians and owners were blinded as to the sponsor); the protocol was approved by Hill's IACUC and the test food was produced by Hill's. Separate from the Hill's colony functional-food study (PMID 27925141). | null | [
"diet",
"supplement",
"renal",
"sdma",
"creatinine",
"client-owned"
] | claude-subagent-batch-C |
beagle-abeta-vaccination-behavioral-enrichment | Aβ vaccination combined with behavioral enrichment in aged beagles | null | controlled_trial | completed | laboratory_colony | Active vaccine against fibrillar Aβ 1-42 (VAC) and behavioral enrichment (ENR), alone and combined | combination | Control/control group: alum-only injections without behavioral enrichment | 0.5 mg fibrillar Aβ with 2% aluminum hydroxide (alum) injected subcutaneously, boosted after 2 weeks and then monthly; control animals received alum injections. Enrichment: two 20-min outdoor group walks weekly, weekly rotation of play toys, and cognitive enrichment tasks | 20 months | {
"n": 34,
"n_note": "34 beagles at study start; groups C/C n=8, C/V n=8, E/C n=8, E/V n=10",
"breed": "Beagle",
"age": "11-12 years (abstract); 10.5-13.6 years at study start (full text)",
"other": "31 dogs from Lovelace Respiratory Research Institute and 3 from Harlan; housed in pairs (n=12) or singly (n=22... | Cognition (learning and memory), brain Aβ and pyroglutamate Aβ, cerebrospinal fluid Aβ42, brain-derived neurotrophic factor mRNA, and microhemorrhages | VAC decreased brain Aβ, pyroglutamate Aβ, increased cerebrospinal fluid Aβ 42 and brain-derived neurotrophic factor RNA levels but also increased microhemorrhages. ENR reduced brain Aβ and prevented microhemorrhages. The combination treatment resulted in a significant maintenance of learning over time, reduced Aβ, and ... | null | null | [] | null | null | [
{
"type": "pmid",
"pmid": "27776266",
"slug": null,
"doi": "10.1016/j.neurobiolaging.2016.09.007",
"title": "Aβ vaccination in combination with behavioral enrichment in aged beagles: effects on cognition, Aβ, and microhemorrhages.",
"year": 2017,
"role": "results",
"quotes": [
... | Thirty-four aged beagles (11-12 years) were assigned, balancing baseline cognitive scores, sex and age, to control, active fibrillar Aβ 1-42 vaccine, behavioral enrichment, or vaccine plus enrichment groups and treated for 20 months. The vaccine (0.5 mg fibrillar Aβ with alum, subcutaneous, boosted at 2 weeks then mont... | Groups were assigned by balancing for baseline cognitive test scores, sex and age rather than by stated randomization, so kind is recorded as controlled_trial. Dogs were housed, and procedures approved, at Lovelace Respiratory Research Institute; the full text has no funding statement. Separate from the earlier antioxi... | null | [
"cognition",
"vaccine",
"amyloid",
"enrichment",
"beagle",
"brain-aging"
] | claude-subagent-batch-B |
labrador-inflammaging-cohort-2018 | Longitudinal analysis of inflammation, immune function and oxidative stress markers in 80 Labrador retrievers from adulthood to end of life | null | longitudinal_cohort | completed | null | null | none | null | null | From adulthood to the end of life | {
"n": 80,
"n_note": "80 Labrador retrievers followed from adulthood to the end of life",
"breed": "Labrador retriever",
"age": "From adulthood to the end of life",
"other": null
} | Changes with age in markers of inflammation (immunoglobulin M, immunoglobulin G, C-reactive protein), oxidative stress (8-hydroxy-2-deoxyguanosine) and the heat shock protein 70 response to heat stress | Serum levels of immunoglobulin M (p < .001) and 8-hydroxy-2-deoxyguanosine (p < .001) increased with age, whereas no effect of age was detected for immunoglobulin G or C-reactive protein unless the last year of life was included in the analysis (p = .002). Baseline levels of heat shock protein 70 decreased with age (p ... | null | null | [] | null | null | [
{
"type": "pmid",
"pmid": "29126143",
"slug": null,
"doi": "10.1093/gerona/glx182",
"title": "Understanding How Dogs Age: Longitudinal Analysis of Markers of Inflammation, Immune Function, and Oxidative Stress.",
"year": 2018,
"role": "results",
"quotes": [
"Detrimental physiol... | Markers of inflammation, immune function and oxidative stress were measured longitudinally in 80 Labrador retrievers from adulthood to the end of life to determine whether dogs undergo inflammaging-like changes. Serum immunoglobulin M and 8-hydroxy-2-deoxyguanosine increased with age, immunoglobulin G and C-reactive pr... | Observational longitudinal study with no intervention; PubMed lists the publication type 'Clinical Trial, Veterinary' but the abstract describes no treatment. The abstract does not state the housing setting, the funder or the calendar years. | null | [
"cohort",
"inflammaging",
"oxidative-stress",
"immune-function",
"labrador-retriever",
"biomarkers"
] | claude-subagent-batch-A |
antioxidant-omega3-enriched-diet-telomere-mobility-shepherd-dogs-2020 | Diet enriched with antioxidants, mitochondrial cofactors and omega-3 fatty acids on telomere length and joint mobility in young and old shepherd dogs | null | randomized_controlled_trial | completed | null | Diet enriched with antioxidants, mitochondrial cofactors and omega-3 fatty acids | diet_or_supplement | Control diet | null | 6 months (measurements at the outset, after 3 and after 6 months) | {
"n": 74,
"n_note": "36 young and 38 old shepherd dogs",
"breed": "shepherd dogs",
"age": "young and old (ages not stated in the abstract)",
"other": null
} | Mean and minimum telomere lengths; minimum and maximum joint angles and range of motion of the shoulder, elbow, carpal, hip, stifle and tarsal joints by computer-assisted gait analysis | A positive influence of the enriched diet on old dogs could be verified for minimum telomere length and all three parameters of the shoulder joint on the side with the higher vertical ground reaction force after 6 months. In the other joints there were less significant differences; in some cases they indicated a contra... | null | null | [] | null | null | [
{
"type": "pmid",
"pmid": "32000015",
"slug": null,
"doi": "10.1016/j.rvsc.2020.01.008",
"title": "Effect of antioxidants, mitochondrial cofactors and omega-3 fatty acids on telomere length and kinematic joint mobility in young and old shepherd dogs - A randomized, blinded and placebo-controlled... | A randomized, blinded, placebo-controlled study fed 36 young and 38 old shepherd dogs either a diet enriched with antioxidants, mitochondrial cofactors and omega-3 fatty acids or a control diet, on the premise that aging-related oxidative stress could be counteracted by such a diet. Telomere length and joint kinematics... | No full text in the corpus; exact ages, diet composition and setting are not stated in the abstract. The total n of 74 is the sum of 36 young and 38 old dogs. | null | [
"diet",
"supplement",
"antioxidant",
"omega-3",
"telomere",
"mobility",
"gait"
] | claude-subagent-batch-C |
triad-rapamycin | Test of Rapamycin in Aging Dogs (TRIAD) | TRIAD | randomized_controlled_trial | ongoing | client_owned | Rapamycin (weekly low-dose) | drug | placebo | Weekly low-dose rapamycin; the rapamycin treatment group receives a cumulative dose of 0.15 mg/kg administered once weekly (as described in the 2023 Texas A&M trial report) | One-year course of weekly rapamycin; lifespan and healthspan endpoints | {
"n": null,
"n_note": null,
"breed": null,
"age": "Healthy, middle-aged dogs",
"other": "Large-breed dogs recruited from Dog Aging Project participants; privately owned; seen every six months at one of seven US veterinary teaching hospitals"
} | Lifespan, plus healthspan metrics (heart and cognitive function, age-related disease incidence) | null | Dog Aging Project (multicenter; seven US veterinary teaching hospitals) | null | [] | 2,021 | null | [
{
"type": "pmid",
"pmid": "39951177",
"slug": null,
"doi": "10.1007/s11357-024-01484-7",
"title": "Test of Rapamycin in Aging Dogs (TRIAD): study design and rationale for a prospective, parallel-group, double-masked, randomized, placebo-controlled, multicenter trial of rapamycin in healthy middl... | TRIAD is a parallel-group, double-masked, randomized, placebo-controlled, multicenter trial that will test whether rapamycin prolongs lifespan and improves healthspan metrics in healthy, middle-aged, large-breed dogs recruited from Dog Aging Project participants. The hypothesis is that a one-year course of weekly low-d... | Design paper only; no results reported. A National Institute on Aging-constituted data and safety monitoring board oversees the trial; the funder is not stated in the abstracts (the Dog Aging Project is supported by NIA U19 AG057377 per the 2023 Texas A&M paper's funding statement). The once-weekly 0.15 mg/kg dose and ... | null | [
"rapamycin",
"lifespan",
"healthspan",
"dog-aging-project",
"multicenter",
"ongoing"
] | claude-subagent-batch-A |
ashwagandha-geriatric-labradors-rct-2024 | Ashwagandha (Withania somnifera) root extract on aging-related changes in healthy geriatric client-owned dogs | null | randomized_controlled_trial | completed | client_owned | Withania somnifera/ashwagandha root extract (ARE) | diet_or_supplement | Placebo control | 15 mg/kg, once daily, orally | 60 days (assessed at initiation, day 30 and day 60); conducted July 2022 to September 2022 | {
"n": 20,
"n_note": "10 dogs in the ARE group and 10 in the placebo group (1:1 randomization)",
"breed": "Labrador",
"age": "aged 8 years or older",
"other": "apparently healthy, obese, client-owned geriatric dogs recruited at a pet clinic in Telangana, India"
} | Serum cortisol, haematological profile, biochemical markers (liver and kidney function), antioxidant indicators and anti-inflammatory responses | Erythrocyte count and haemoglobin were significantly increased with ARE (p < 0.001) and leukocyte count decreased (p < 0.05); liver function markers (ALT, AST, albumin, globulin; p < 0.001 at day 60) and kidney function markers (creatinine, BUN; p < 0.001 at days 30 and 60) decreased in ARE-treated dogs compared to pla... | College of Veterinary Science, P.V.N.R. Telangana Veterinary University, Hyderabad (ethics approval); conducted at Cure Pet Clinic, Hanamkonda, Telangana, India | None stated (funding information: None) | [] | 2,022 | 2,022 | [
{
"type": "pmid",
"pmid": "39078383",
"slug": null,
"doi": "10.1002/vms3.1556",
"title": "Effects of ashwagandha (Withania somnifera) root extract on aging-related changes in healthy geriatric dogs: A randomized, double-blinded placebo-controlled study.",
"year": 2024,
"role": "results",... | A randomized, double-blind, placebo-controlled trial at a pet clinic in Telangana, India (July to September 2022) enrolled 20 apparently healthy, obese, client-owned geriatric Labradors aged 8 years or older and gave 10 of them ashwagandha root extract at 15 mg/kg orally once daily and 10 a placebo, to test whether ARE... | Separate trial from the ashwagandha gut-parameter study in research Beagles (PMID 39911483): different animals, setting and ethics approval. | null | [
"supplement",
"ashwagandha",
"adaptogen",
"inflammation",
"oxidative-stress",
"cortisol"
] | claude-subagent-batch-C |
fortetropin-senior-dogs-mobility-rct-2022 | Fortetropin in geriatric and senior dogs with reduced mobility | null | randomized_controlled_trial | completed | null | Fortetropin, a nonthermal-pasteurized, freeze-dried, fertilized egg yolk product | diet_or_supplement | Placebo | null | 12 weeks (mobility scores at week 6 and week 12) | {
"n": null,
"n_note": null,
"breed": null,
"age": "senior dogs",
"other": "geriatric and senior dogs with reduced mobility"
} | Mobility scores from the Liverpool Osteoarthritis in Dogs (LOAD) questionnaire | Mild, but statistically significant, improvement of the mobility scores for the treatment group at both week 6 (P = 0.03) and week 12 (P = 0.006) compared to the baseline score. No statistical improvement was noted at any time in the placebo group or between the treatment and placebo group. | null | null | [] | null | null | [
{
"type": "pmid",
"pmid": "36185794",
"slug": null,
"doi": null,
"title": "Evaluation of Fortetropin in geriatric and senior dogs with reduced mobility.",
"year": 2022,
"role": "results",
"quotes": [
"As pets age, quality of life and mobility can be affected by pain of osteoart... | A randomized, double-blinded, placebo-controlled study evaluated Fortetropin, a freeze-dried fertilized egg yolk product, on mobility in senior dogs, motivated by age-related muscle atrophy and osteoarthritis pain. Mobility was scored with the owner-completed LOAD questionnaire. The treatment group showed mild but stat... | No full text in the corpus: number of dogs, dose and setting are not stated in the abstract. The client-based LOAD survey implies owner-assessed dogs. P values are quoted around inline italic tags in the abstract. | null | [
"supplement",
"mobility",
"sarcopenia",
"fortetropin",
"load"
] | claude-subagent-batch-C |
ly-d6-2-senolytic-nad-precursor-senior-dogs-rct-2024 | LY-D6/2 senolytic and NAD+ precursor combination in senior companion dogs with mild to moderate cognitive impairment | LY-D6/2 | randomized_controlled_trial | completed | client_owned | LY-D6/2, a proprietary combination of a senolytic (LY-D6) and an NAD+ precursor (LY-D2), given at low or full dose | diet_or_supplement | Placebo | NAD+ precursor (or placebo) capsule(s) once daily and the senolytic (or placebo) capsule(s) on two consecutive days each month; low or full dose (amounts not disclosed) | 6 months (3-month primary endpoint, 6-month secondary endpoint) | {
"n": 70,
"n_note": "70 enrolled and allocated to placebo, low or full dose; 59 completed the 3-month primary endpoint and 51 the 6-month secondary endpoint; randomized in blocks of 9 (3 per group)",
"breed": null,
"age": "10 years or older",
"other": "companion dogs with mild to moderate cognitive impairmen... | Change in owner-reported Canine Cognitive Dysfunction Rating (CCDR) scale score and change in activity measured with collar-mounted physical activity monitors at 3 months | There was a significant difference in CCDR score across treatment groups from baseline to the primary endpoint (p = 0.02) with the largest decrease in the full dose group. No difference was detected between groups using in house cognitive testing, and no significant differences between groups in changes in measured act... | North Carolina State University College of Veterinary Medicine | Animal Bioscience, Boston MA | [] | 2,022 | null | [
{
"type": "pmid",
"pmid": "38811634",
"slug": null,
"doi": "10.1038/s41598-024-63031-w",
"title": "A randomized, controlled clinical trial demonstrates improved owner-assessed cognitive function in senior dogs receiving a senolytic and NAD+ precursor combination.",
"year": 2024,
"role": ... | A blinded, three-arm randomized controlled trial at North Carolina State University enrolled 70 companion dogs aged 10 years or older with mild to moderate cognitive impairment and allocated them to placebo, low-dose or full-dose LY-D6/2, a proprietary senolytic plus NAD+ precursor combination given as a daily NAD+ pre... | Dose amounts are proprietary and not disclosed. Recruitment ran January 2022 through June 2023; no trial registration is mentioned in the full text. | null | [
"senolytic",
"nad",
"supplement",
"cognition",
"frailty",
"activity",
"client-owned"
] | claude-subagent-batch-C |
cow-placenta-extract-cognition-aged-dogs-rct-2026 | Cow placenta extract (CPE) on cognitive function and oxidative stress in aged client-owned dogs | null | randomized_controlled_trial | completed | client_owned | Cow placenta extract (CPE) oral capsules | diet_or_supplement | Placebo capsules identical in appearance, same dosage, method and duration | 200 mg CPE orally for dogs weighing 5-15 kg and 400 mg for dogs over 15 kg, twice daily for 6 months | 6 months (CSLB at months 2, 4 and 6) | {
"n": 88,
"n_note": "88 dogs completed the trial and are reported (45 CPE, 43 placebo); 94 enrolled, 3 lost to follow-up, 1 died, 2 excluded for noncompliance",
"breed": null,
"age": "aged dogs >= 7 years per the abstract; over 8 years of age per the full-text inclusion criteria",
"other": "client-owned dogs... | Canine Social and Learning Behavior Survey (CSLB) score; serum oxidative stress markers (MDA, GSH-Px, GSH and others) | By month 6, mean CSLB was 35.1 +/- 4.9 in the CPE group vs 41.1 +/- 5.3 in the placebo group (P < .05; Cohen's d = -1.17). The successful therapeutic response was 77.8% in the CPE group vs 9.3% in the placebo group (P < .001). Change in CSLB correlated positively with change in MDA (r = 0.77) and negatively with change... | Jiangsu Agri-animal Husbandry Vocational College, China (ethics committee); 3 animal clinics in the eastern region of China | null | [] | 2,023 | 2,024 | [
{
"type": "pmid",
"pmid": "42492061",
"slug": null,
"doi": "10.1093/jvimsj/aalag125",
"title": "Effects of cow placenta extract on cognitive function in aged dogs: a randomized controlled trial.",
"year": 2026,
"role": "results",
"quotes": [
"Cow placenta extract (CPE) has demo... | A 6-month randomized, blinded, placebo-controlled trial in eastern China enrolled client-owned aged dogs (over 7-8 years, more than 5 kg) with a CSLB cognitive score of 30 or more from three animal clinics; 88 dogs completed the trial (45 CPE, 43 placebo). Dogs received cow placenta extract capsules (200 mg for 5-15 kg... | Start year is the baseline survey window (December 2023 to January 2024); end year 2024 follows from the 6-month duration after baseline. The abstract gives the age criterion as >= 7 years while the full text says over 8 years. No funding source is named beyond the project covering veterinary examination costs. | null | [
"supplement",
"placenta-extract",
"cognition",
"oxidative-stress",
"cslb",
"client-owned"
] | claude-subagent-batch-C |
dog-aging-project | Dog Aging Project (DAP) long-term longitudinal study of ageing in companion dogs | DAP | longitudinal_cohort | ongoing | client_owned | null | none | null | null | Long-term; data and biospecimens collected annually, with dogs enrolled for the dog's lifetime | {
"n": 30000,
"n_note": "Over 30,000 canine participants and their owners at the time of the 2022 design paper, described as tens of thousands of companion dogs; five overlapping cohorts (Pack, Foundation, Precision, TRIAD and a cross-sectional Centenarian sample)",
"breed": "All breeds (both purebred and mixed b... | Identify the genetic, environmental and lifestyle factors associated with healthy lifespan; characterize ageing on multimorbidity, frailty and inflammageing; whole-genome sequencing of at least 10,000 dogs; metabolome, epigenome and microbiome biomarkers of ageing | null | null | National Institute on Aging (NIA U19 AG057377), as cited in the funding statement of the 2023 Texas A&M rapamycin trial | [] | null | null | [
{
"type": "pmid",
"pmid": "35110758",
"slug": null,
"doi": "10.1038/s41586-021-04282-9",
"title": "An open science study of ageing in companion dogs.",
"year": 2022,
"role": "design",
"quotes": [
"The Dog Aging Project is a long-term longitudinal study of ageing in tens of thou... | The Dog Aging Project is a long-term, open-data longitudinal study of ageing in tens of thousands of privately owned companion dogs of all breeds, ages, sizes and sexes across the USA, with over 30,000 participants at the time of the 2022 design paper. It collects survey, environmental, veterinary-record, genome-sequen... | Design paper. The TRIAD randomized trial (triad-rapamycin) and the Precision cohort (dog-aging-project-precision-cohort) are recorded separately. The lead institution is not named in the sources (more than 20 academic institutions participate); the NIA grant number is quoted from another paper's funding statement. Data... | null | [
"cohort",
"dog-aging-project",
"open-data",
"longitudinal",
"biomarkers",
"genomics"
] | claude-subagent-batch-A |
old-dog-padua-cohort | OLD-DOG Project: 30-month prospective biomarkers-of-aging cohort of 209 companion dogs (University of Padua) | OLD-DOG | longitudinal_cohort | ongoing | client_owned | null | none | null | null | 30-month prospective study with comprehensive evaluations every six months | {
"n": 209,
"n_note": "209 privately owned dogs enrolled and assessed at baseline; survival status available for 206 dogs at the fourth time point",
"breed": "Multi-breed cohort",
"age": "Aged 5 years and over (dogs aged over five years with at least the month of birth known)",
"other": "Located in the Veneto... | Identification and validation of biomarkers of aging (physiological, biochemical, hematological and behavioral parameters, microbiota profiles, telomere length, DNA methylation) and their predictive value for healthspan and lifespan | Preliminary cross-sectional analyses have identified consistent age-related patterns across multiple domains, including hematological and biochemical indices, inflammatory markers, and measures of physical and cognitive performance. The frailty index showed a moderate correlation with chronological age (ρ=0.56, p < .00... | University of Padua's Veterinary Teaching Hospital | Italian Ministry of University and Research (MUR), PRIN grant 20228NKPNH | [] | 2,023 | null | [
{
"type": "pmid",
"pmid": "41860870",
"slug": null,
"doi": "10.1016/j.tjfa.2026.100145",
"title": "OLD DOG - Validating the dog as an animal model for human aging studies.",
"year": 2026,
"role": "design",
"quotes": [
"The OLD-DOG Project, launched in 2023 at the University of ... | The OLD-DOG Project, launched in 2023 at the University of Padua's Veterinary Teaching Hospital, is a 30-month prospective observational study of 209 privately owned, multi-breed dogs aged 5 years and over from the Veneto region of Italy, evaluated every six months with clinical examinations, physical fitness testing, ... | Observational cohort with no intervention. Ethics approval by the University of Padua ethical committee (protocol number 215906, released 31/10/2023) is not a trial registry entry. End year not stated. | null | [
"cohort",
"biomarkers",
"frailty",
"italy",
"longitudinal",
"biological-age"
] | claude-subagent-batch-A |
rapamycin-10-week-rct-2017 | Short-term (10-week) rapamycin randomized controlled trial in 24 middle-aged companion dogs | null | randomized_controlled_trial | completed | client_owned | Rapamycin at a non-immunosuppressive dose | drug | placebo | 0.05 mg/kg three times weekly in one rapamycin treatment group and 0.1 mg/kg three times weekly in another rapamycin treatment group (as described in the 2023 Texas A&M follow-up trial); the 2017 abstract states only a non-immunosuppressive dose for 10 weeks | 10 weeks | {
"n": 24,
"n_note": "24 middle-aged healthy dogs received either placebo or rapamycin",
"breed": null,
"age": "Middle-aged; mean age of 9.7 years (as reported in the 2023 follow-up trial)",
"other": "Healthy pet dogs"
} | Safety of low-dose rapamycin (clinical and hematological exams before, during and after the trial) and echocardiographic measures of heart function before and after the trial | No clinical side effects in the rapamycin-treated group compared to dogs receiving the placebo. Echocardiography suggested improvement in both diastolic and systolic age-related measures of heart function (E/A ratio, fractional shortening, and ejection fraction) in the rapamycin-treated dogs. Hematological values remai... | null | null | [] | null | null | [
{
"type": "pmid",
"pmid": "28374166",
"slug": null,
"doi": "10.1007/s11357-017-9972-z",
"title": "A randomized controlled trial to establish effects of short-term rapamycin treatment in 24 middle-aged companion dogs.",
"year": 2017,
"role": "results",
"quotes": [
"In this study... | Twenty-four middle-aged healthy pet dogs received placebo or a non-immunosuppressive dose of rapamycin for 10 weeks in a randomized controlled trial whose primary goal was establishing safety, with echocardiography before and after treatment. No clinical side effects were seen in the rapamycin group, and echocardiograp... | The 2016 pharmacokinetic paper (5 purpose-bred hounds, 0.1 mg/kg orally, University of Tennessee IACUC) is grouped here as the pharmacokinetic companion per the registry's grouping decision; its abstract frames its purpose around tumor-bearing dogs and does not itself reference the 10-week trial. Dose groups, randomiza... | null | [
"rapamycin",
"cardiac-function",
"safety",
"companion-dogs",
"short-term",
"pharmacokinetics"
] | claude-subagent-batch-A |
rapamycin-6-month-rct-tamu-2023 | Six-month low-dose rapamycin masked placebo-controlled randomized trial in 17 healthy client-owned dogs (Texas A&M) | null | randomized_controlled_trial | completed | client_owned | Low-dose rapamycin | drug | Placebo (lactose capsules identical in appearance) | 0.025 mg/kg rapamycin per dose, orally in capsules, three times per week (Monday, Wednesday and Friday mornings), rounded to the nearest 0.25 mg capsule | 6 months of treatment; evaluations at baseline, 3, 6 and 12 months (final examination 6 months after discontinuation) | {
"n": 17,
"n_note": "17 dogs enrolled and randomized: 9 rapamycin, 8 placebo; the initial design sought 50 dogs but enrollment ceased early",
"breed": null,
"age": "6-10 years (mean 7.8 years in the rapamycin group and 8.5 years in the placebo group)",
"other": "Weighing 18-36 kg, without significant systemi... | Echocardiographic indices of diastolic and systolic cardiac function at 6 and 12 months, and occurrence of adverse events; impact on routine clinical pathology was a secondary objective | There were no statistically significant differences in echocardiographic parameters between rapamycin and placebo groups at 6 or 12 months. No clinically significant adverse events occurred. In 26.8% of the bi-weekly surveys owners whose dogs received rapamycin reported perceived positive changes in behavior or health,... | Texas A&M University (TAMU) Veterinary Medical Teaching Hospital (VMTH) | William H. Donner Foundation; additional support for some authors from the Dog Aging Project (NIA U19 AG057377) | [] | null | null | [
{
"type": "pmid",
"pmid": "37275618",
"slug": null,
"doi": "10.3389/fvets.2023.1168711",
"title": "A masked, placebo-controlled, randomized clinical trial evaluating safety and the effect on cardiac function of low-dose rapamycin in 17 healthy client-owned dogs.",
"year": 2023,
"role": "... | Seventeen healthy client-owned dogs aged 6-10 years and weighing 18-36 kg were randomized at the Texas A&M veterinary teaching hospital to low-dose rapamycin (0.025 mg/kg three times per week) or identical placebo capsules for 6 months, with echocardiography and clinical pathology at baseline, 6 and 12 months. There we... | The IACUC and Clinical Research Review Committee protocol number 2017–0125 is an ethics approval, not a trial registry entry. Enrollment ceased early (17 of a planned 50 dogs) because of recruitment difficulty and the launch of the multi-center TRIAD trial. This paper is also cited as a follow-up source in rapamycin-10... | null | [
"rapamycin",
"cardiac-function",
"safety",
"client-owned",
"placebo-controlled",
"texas-a-m"
] | claude-subagent-batch-A |
ashwagandha-gut-parameters-geriatric-beagles-rct-2024 | Ashwagandha root extract on gut parameters in healthy geriatric research Beagles | null | randomized_controlled_trial | completed | laboratory_colony | Withania somnifera/Ashwagandha root extract (ARE; KSM-66) capsules | diet_or_supplement | Placebo (starch-filled capsules identical in appearance) | 15 mg/kg body weight, once daily, orally, for 2 months | 2 months (assessed on day 0, day 30 and day 60) | {
"n": 12,
"n_note": "6 placebo and 6 ARE",
"breed": "Beagle",
"age": "12-15 years",
"other": "healthy geriatric dogs bred for research purposes, approximately 11 kg, housed at a certified kennel in Hyderabad, Telangana, India"
} | Serum haematology, biochemical markers, stool parameters (faecal score and pH) and gut-microbiome parameters (faecal short chain fatty acids, L-citrulline, intestinal-type alkaline phosphatase, lactate, carbamoyl-phosphate synthase) | Erythrocyte counts and haemoglobin were significantly increased with ARE; serum ALT and AST significantly decreased at day 60 compared with placebo; L-citrulline was significantly modulated while I-ALP, lactate and CPS were unaffected; faecal score reduced significantly (p < 0.001) while faecal pH was unaltered; propio... | null | KSM-66 ashwagandha root extract and corn starch placebo provided as gift samples by Ixoreal BioMed, Inc., Los Angeles, CA (no other funding stated) | [] | null | null | [
{
"type": "pmid",
"pmid": "39911483",
"slug": null,
"doi": "10.3389/fvets.2024.1491989",
"title": "The role of Ashwagandha in modulating gut parameters in dogs-a randomized double-blind placebo-controlled trial.",
"year": 2024,
"role": "results",
"quotes": [
"/Ashwagandha root ... | A randomized, double-blind, placebo-controlled trial in Telangana, India randomly divided 12 healthy geriatric research Beagles aged 12-15 years, housed at a certified kennel, into ARE (KSM-66 ashwagandha root extract, 15 mg/kg orally once daily for 2 months; n = 6) and starch placebo (n = 6) groups, hypothesising that... | Separate from the client-owned Labrador ashwagandha trial (PMID 39078383); different animals, kennel setting and a 2023 ethics approval. Lead organization not stated explicitly in the extracted text (ethics approval number references CVSC-WGL). | null | [
"supplement",
"ashwagandha",
"gut",
"microbiome",
"scfa",
"beagle",
"colony"
] | claude-subagent-batch-C |
beagle-middle-aged-enrichment-tacrolimus-q134r-brain-atrophy | Behavioral enrichment with tacrolimus or Q134R in middle-aged beagles: longitudinal MRI brain atrophy study | null | longitudinal_cohort | completed | null | Chronic treatment with the calcineurin inhibitor tacrolimus or the NFAT-inhibiting compound Q134R, in dogs undergoing behavioral enrichment | combination | null | null | null | {
"n": 43,
"n_note": "36 females, 7 males",
"breed": "Beagle",
"age": "middle-aged",
"other": null
} | Age-related brain atrophy on annual MRI (region-of-interest-based and voxel-based volumetrics of frontal lobe, caudate nucleus and hippocampus) | We found that the frontal lobe showed accelerated atrophy with age, while the caudate nucleus remained relatively stable. Remarkably, the hippocampus increased in volume in all dogs. None of these changes were influenced by tacrolimus or Q134R treatment. Our results suggest that behavioral enrichment can prevent atroph... | null | null | [] | null | null | [
{
"type": "pmid",
"pmid": "38561226",
"slug": null,
"doi": "10.1523/jneurosci.2366-23.2024",
"title": "Age-Related Brain Atrophy and the Positive Effects of Behavioral Enrichment in Middle-Aged Beagles.",
"year": 2024,
"role": "results",
"quotes": [
"Here we examined the effect... | A longitudinal study followed 43 middle-aged beagles (36 females, 7 males) undergoing behavioral enrichment and chronically treated with tacrolimus or Q134R, with annual MRI analysed by automated regional and voxel-based volumetrics. The frontal lobe atrophied at an accelerating rate with age, the caudate nucleus staye... | Kind follows the abstract's wording (a longitudinal study in middle-aged beagles undergoing behavioral enrichment); the study also chronically treats dogs with tacrolimus or Q134R, but the abstract does not describe the treatment arms, comparator, dosing or study length, so those fields are null. Separate from the earl... | null | [
"brain-aging",
"enrichment",
"mri",
"beagle",
"tacrolimus",
"q134r",
"longitudinal"
] | claude-subagent-batch-B |
loyal-stay-loy-002 | STAY study: LOY-002 for healthy lifespan extension in senior dogs (Loyal) | STAY | regulatory_program | ongoing | client_owned | LOY-002, a prescription daily pill targeting age-related metabolic dysfunction | drug | placebo | daily oral tablet (dose not disclosed) | four-year study | {
"n": 1300,
"n_note": "enrolment completed July 2025 at 70 veterinary clinics in the US (initial goal 1,000 dogs, expanded by 300)",
"breed": "any; dogs of nearly every size",
"age": "10 years or older, weighing at least 14 lb",
"other": null
} | lifespan and quality of life compared with placebo; adverse effects | null | Loyal (San Francisco) | Loyal | [] | 2,024 | null | [
{
"type": "web",
"pmid": null,
"slug": "dvm360-stay-enrollment",
"doi": null,
"title": "Clinical trial for Longevity drug meets goal of enrolling 1000 dogs (dvm360)",
"year": 2025,
"role": "press",
"quotes": [
"The STAY study, a clinical trial investigating the developmental lo... | The STAY study is Loyal's pivotal, placebo-controlled, four-year field trial of LOY-002, a daily pill intended to extend healthy lifespan in dogs aged 10 years or older weighing at least 14 lb. Enrolment reached 1,000 dogs at 70 US veterinary clinics and was expanded to 1,300, completing in July 2025. The FDA Center fo... | Company- and trade-press-sourced; no peer-reviewed publication of design or results as of 2026-10-01. The drug's mechanism and dose are not disclosed beyond 'targets age-related metabolic dysfunction'. | null | [
"lifespan",
"drug",
"senior-dogs",
"pivotal-trial",
"fda-conditional-approval",
"loyal"
] | claude-hand-curated |
vaccs-cancer-preventative-vaccine | Vaccination Against Canine Cancer Study (VACCS) | VACCS | randomized_controlled_trial | ongoing | client_owned | Cancer preventative vaccine targeting frameshift neoantigens conserved across multiple species and tumor histologies | vaccine | placebo | null | null | {
"n": null,
"n_note": "Described as the largest interventional cancer clinical trial conducted in companion dogs to date; enrollment number not stated in the abstract",
"breed": null,
"age": null,
"other": "Companion dogs"
} | Cumulative incidence (CI) of dogs developing malignant neoplasia of any type at the end of the study period, in addition to safety and immunogenicity; secondary endpoints are changes in incidence of specific tumor types, survival times following neoplasia diagnosis, and all-cause mortality | null | null | null | [] | null | null | [
{
"type": "pmid",
"pmid": "38056066",
"slug": null,
"doi": "10.1016/j.vetimm.2023.110691",
"title": "Design of a randomized, placebo-controlled study evaluating efficacy and safety of a cancer preventative vaccine in dogs.",
"year": 2024,
"role": "design",
"quotes": [
"Identifi... | VACCS is a randomized, placebo-controlled study protocol testing a cancer preventative vaccine against frameshift neoantigens in companion dogs, described as the largest interventional cancer clinical trial conducted in companion dogs to date. Its primary endpoint is the cumulative incidence of malignant neoplasia of a... | Protocol paper. The design wording 'randomized, placebo-controlled' comes from the paper title (Design of a randomized, placebo-controlled study evaluating efficacy and safety of a cancer preventative vaccine in dogs), which the abstract body does not restate; the abstract gives no age range, enrollment number, dose sc... | null | [
"vaccine",
"cancer-prevention",
"companion-dogs",
"ongoing",
"neoantigen"
] | claude-subagent-batch-A |
dog-aging-project-precision-cohort | Dog Aging Project Precision cohort (multi-omic longitudinal sub-cohort of 1,000 dogs) | null | longitudinal_cohort | ongoing | client_owned | null | none | null | null | Annual biospecimen collection; second- and third-year samples already being collected | {
"n": 1000,
"n_note": "One thousand dog-owner pairs recruited; blood, urine, fecal and hair samples collected and processed from 976 dogs",
"breed": null,
"age": null,
"other": "Recruited into cohort strata based on life stage, sex, size and geography; samples collected by primary care veterinarians"
} | Mechanisms underlying age-related change in the metabolome, microbiome and epigenome; data include complete blood count, chemistry profile, immunophenotyping by flow cytometry, metabolite quantification, fecal microbiome characterization, epigenomic profile and urinalysis | The project demonstrates that scientifically useful biospecimens can be collected from a geographically dispersed population through collaboration with private veterinary clinics and downstream labs; no age-related findings are reported in the design paper. | Dog Aging Project | null | [] | null | null | [
{
"type": "pmid",
"pmid": "40038157",
"slug": null,
"doi": "10.1007/s11357-025-01571-3",
"title": "Rationale and design of the Dog Aging Project precision cohort: a multi-omic resource for longitudinal research in geroscience.",
"year": 2025,
"role": "design",
"quotes": [
"The ... | The Precision cohort is a Dog Aging Project sub-cohort of one thousand dog-owner pairs recruited into strata by life stage, sex, size and geography to study age-related change in the metabolome, microbiome and epigenome of companion dogs. Blood, urine, fecal and hair samples were collected from 976 dogs by primary care... | Sub-study of the Dog Aging Project (parent record dog-aging-project). Funder not stated in the abstract. | dog-aging-project | [
"cohort",
"dog-aging-project",
"multi-omic",
"biomarkers",
"precision-cohort"
] | claude-subagent-batch-A |
ef-m2-immutalon-geri-vital-dog-rct-2025 | EF-M2 (Immutalon) macrophage glyco-modulation for activity and vitality in aging companion dogs (GERI-VITAL-DOG) | GERI-VITAL-DOG | randomized_controlled_trial | completed | client_owned | Subcutaneous EF-M2 (Immutalon), a GcMAF-derived protein for macrophage-targeted glyco-modulation | drug | Matched placebo (identical 0.9% sodium chloride vehicle, mirror injections and mirror step-up) | 0.1 ug/kg (0.1 mL/kg) subcutaneously every 72 h for 4 weeks, with protocolized blinded step-up to every 48 h at day 14 for partial responders; followed by 4 weeks off-treatment | 4 weeks of treatment plus 4 weeks off-treatment (assessments to day 56) | {
"n": 60,
"n_note": "60 randomized (30 EF-M2; 30 placebo), intention-to-treat population",
"breed": null,
"age": ">= 10 years; mean age 12.4 +/- 1.8 y",
"other": "client-owned geriatric dogs, clinically stable, at two referral veterinary clinics in Novosibirsk, Russia"
} | Co-primary endpoints tested hierarchically: change in accelerometer-measured active minutes/day at week 1 and change in a day-28 vitality composite (z-score of inverted CBPI-PSS, HRQL-vitality and appetite VAS) | EF-M2 was superior to placebo on both co-primary endpoints: +23.05 min/day at week 1 (95% CI, 18.16-27.94; p < 0.001) and +2.01 z-units at day 28 (95% CI, 1.52-2.50; p < 0.001). Key secondaries favored EF-M2, including greater week-4 activity (+33.00 min/day), lower BAER auditory threshold (-5.28 dB) and reduced transe... | Center for New Medical Technologies (Novosibirsk, Russia) and Triangel Scientific Research Laboratory (San Francisco, CA, USA); conducted at VEGA Veterinary Clinic and BALTO Veterinary Clinic, Novosibirsk | Activator MAF, LLC (Novosibirsk, Russia): supplied Immutalon and provided unrestricted financial support | [] | null | null | [
{
"type": "pmid",
"pmid": "41472148",
"slug": null,
"doi": "10.3390/vetsci12121168",
"title": "Precision Glyco-Modulation of Macrophages with EF-M2 (Immutalon<sup>TM</sup>) Improves Function and Lowers Inflammatory Biomarkers in Aging Dogs: A Double-Blind, Placebo-Controlled Trial.",... | GERI-VITAL-DOG was a multicenter, randomized, double-blind, placebo-controlled trial at two referral clinics in Novosibirsk, Russia that randomized 60 client-owned geriatric dogs (10 years or older, mean 12.4 years) 1:1 to subcutaneous EF-M2 (Immutalon) at 0.1 ug/kg every 72 h for 4 weeks, with a blinded step-up to eve... | No trial registration is mentioned; clinic IACUC approvals are dated January 2025 and the protocol version is dated November 2024. The abstract renders the dose as 0.1 μg/kg; the full text uses the micro sign in 1 µg/mL. | null | [
"drug",
"immunomodulation",
"macrophage",
"activity",
"vitality",
"inflammaging",
"client-owned"
] | claude-subagent-batch-C |
es-msc-and-ev-geriatric-small-dogs-cognition-mobility-pilot-2025 | Human embryonic stem cell-derived MSCs and MSC extracellular vesicles in geriatric small dogs with cognitive and behavioral changes (pilot) | null | pilot_study | completed | client_owned | Human embryonic stem cell-derived mesenchymal stem cells (ES-MSCs) by a single intravenous injection, or ES-MSC-derived extracellular vesicles (ES-MSC-EVs) by two subcutaneous injections | cell_or_gene_therapy | None (two active arms compared; no placebo or untreated group) | ES-MSC: single intravenous injection of 1.0 x 10^7 cells for dogs 3-7 kg or 2.0 x 10^7 cells for dogs 7-12 kg; ES-MSC-EV: 1.0 x 10^10 particles per dog subcutaneously on the first day and 1 week later | 2 weeks after treatment | {
"n": 42,
"n_note": "21 ES-MSC and 21 ES-MSC-EV; 43 recruited, 42 participated",
"breed": "Maltese and Miniature Poodle most common; mixed small breeds",
"age": "11 years or older; median age 14 years (ES-MSC) and 13 years (ES-MSC-EV)",
"other": "geriatric small dogs (3 to 12 kg) exhibiting cognitive and beh... | Canine Cognitive Dysfunction Rating (CCDR) and Liverpool Osteoarthritis in Dogs (LOAD) scores before and 2 weeks after treatment; safety by complete blood count and serum chemistry | No notable side effects were detected in either group, and the questionnaire survey revealed that both groups showed alleviation in CCDR and LOAD scores following administration. | Daewoong Pharmaceutical Co., Ltd., Republic of Korea (cell production and IACUC approval) with Helix Animal Hospital, Korean Animal Cancer Center and Songjeong Animal Medical Center, Seoul | No financial support declared; several authors employed by Daewoong Co., Ltd. and Daewoong Pet, Corp. | [] | null | null | [
{
"type": "pmid",
"pmid": "40206251",
"slug": null,
"doi": "10.3389/fvets.2025.1549870",
"title": "Evaluation of cognitive and mobility function in geriatric dogs following treatment with stem cell and stem cell extracellular vesicles derived from embryonic stem cells: a pilot study.",
"year... | A pilot study at three animal hospitals in Seoul randomly divided 42 client-owned geriatric small dogs (11 years or older, 3-12 kg, mostly Maltese and Miniature Poodles) with cognitive and behavioral changes into a group given one intravenous dose of human embryonic stem cell-derived mesenchymal stem cells (n = 21) and... | Two active arms with no control group and only a 2-week follow-up; cells are human ESC-derived and produced by Daewoong Pharmaceutical, whose employees are among the authors. | null | [
"stem-cells",
"extracellular-vesicles",
"cognition",
"mobility",
"pilot",
"client-owned"
] | claude-subagent-batch-C |
loyal-loy-001-large-dogs | LOY-001: IGF-1-lowering long-acting injection for large and giant breed dogs (Loyal) | LOY-001 | regulatory_program | ongoing | null | LOY-001, a prescription long-acting injection that reduces IGF-1 levels | drug | null | injection administered by a veterinarian every three to six months | null | {
"n": null,
"n_note": null,
"breed": "large and giant breeds",
"age": "7 years and older, weighing at least 40 lb",
"other": null
} | healthy lifespan extension | null | Loyal (San Francisco) | Loyal | [] | null | null | [
{
"type": "web",
"pmid": null,
"slug": "loyal-for-dog-owners",
"doi": null,
"title": "Loyal: for dog owners (company page)",
"year": 2026,
"role": "company",
"quotes": [
"LOY-001 is a prescription long-acting injection, while LOY-003 is a prescription daily pill.",
"LOY-0... | LOY-001 is Loyal's long-acting injectable intended to extend healthy lifespan in large and giant breed dogs aged 7 years or older weighing at least 40 lb by lowering IGF-1, given every three to six months. The FDA accepted its reasonable-expectation-of-effectiveness technical section in 2023. No trial design or results... | Company- and press-sourced only; trial size, design and results undisclosed as of 2026-10-01. | null | [
"lifespan",
"drug",
"igf-1",
"large-breeds",
"fda-conditional-approval",
"loyal"
] | claude-hand-curated |
loyal-loy-003-large-dogs-pill | LOY-003: IGF-1-lowering daily pill for large breed dogs (Loyal) | LOY-003 | regulatory_program | ongoing | null | LOY-003, a prescription daily pill targeting IGF-1 over-expression | drug | null | daily oral tablet (dose not disclosed) | null | {
"n": null,
"n_note": null,
"breed": "large breeds",
"age": "5 years and older, weighing at least 60 lb",
"other": null
} | healthy lifespan extension | null | Loyal (San Francisco) | Loyal | [] | null | null | [
{
"type": "web",
"pmid": null,
"slug": "loyal-for-dog-owners",
"doi": null,
"title": "Loyal: for dog owners (company page)",
"year": 2026,
"role": "company",
"quotes": [
"LOY-001 is a prescription long-acting injection, while LOY-003 is a prescription daily pill.",
"LOY-0... | LOY-003 is Loyal's daily pill counterpart to LOY-001, intended for large breed dogs aged 5 years or older weighing at least 60 lb and targeting IGF-1 over-expression. The company reports that its reasonable-expectation-of-effectiveness section was completed in 2026. No trial design or results have been published. | Company- and press-sourced only; developed with Crinetics Pharmaceuticals according to the company; trial details undisclosed as of 2026-10-01. | null | [
"lifespan",
"drug",
"igf-1",
"large-breeds",
"fda-conditional-approval",
"loyal"
] | claude-hand-curated |
Canine aging trial registry
A registry of interventional studies and longitudinal cohorts on aging in dogs: lifespan and healthspan trials (rapamycin, diet restriction, L-deprenyl, the Dog Aging Project's TRIAD), cognitive-aging and mobility trials in senior dogs, immunosenescence and organ-decline interventions, cancer-prevention trials in older dogs, lifetime cohorts (Dog Aging Project, Golden Retriever Lifetime Study), and company regulatory programs for lifespan-extension drugs (Loyal's STAY study of LOY-002, LOY-001, LOY-003).
Veterinary trials are not registered on ClinicalTrials.gov and company programs are known only from announcements, so no such registry existed. Each record is typed (design, status, setting, intervention and class, comparator, dose regimen, duration, population, primary outcome, result as the source states it, organisation, registration ids, sources) and every field is backed by a verbatim quote from the cited source; a validator refuses records whose quotes cannot be found in the cited abstract, full text or page snapshot.
Files
| File | Contents |
|---|---|
canine_trials.jsonl |
one record per study (schema in schema.json) |
canine_trials.csv |
flat export of the main fields |
schema.json |
JSON Schema 2020-12 |
sources/web/*.txt, sources/web_index.json |
text snapshots of company and press pages quoted by web sources, with URL, date and hash |
sources/europepmc/*.json |
abstracts of peer-reviewed sources outside the canine-aging-corpus |
Quotes from pmid sources are checked against the
canine-aging-corpus abstracts
and full texts.
Provenance and caveats
v0 (2026-10-01): candidates were screened from the corpus (trial-tagged records and
trial-vocabulary searches) and drafted by model-assisted extraction in batches, plus
hand-written company records; all quotes validated; no domain-expert review yet. Records of
kind regulatory_program rest on company and press sources only and say so in notes.
Disease-treatment trials framed around a disease rather than aging are out of scope.
Source code, validator and contribution guide: https://github.com/w0lph/k9/tree/main/trials.
The registry is served as canine_trial_search by the
dog-geroscience-mcp server
and as pages at https://w0lph.github.io/k9/trials/.
Licence
Registry text CC BY 4.0. Quotes are short excerpts used for verification and attribution; the cited articles keep their own licences. Snapshots of company and press pages are kept for verification only.
- Downloads last month
- 38